RTC
NBIX icon

Riverview Trust Company’s Neurocrine Biosciences NBIX Stock Holding History

Riverview Trust Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-176
Closed -$19.5K – 454
2025
Q1 		$19.5K Sell
176
-5
-3% -$633 0.02% 437
2024
Q4 		$24.7K Buy
181
+5
+3% +$618 0.02% 381
2024
Q3 		$20.3K Hold
176
– – 0.02% 470
2024
Q2 		$24.2K Hold
176
– – 0.02% 366
2024
Q1 		$24.3K Buy
+176
New +$24K 0.02% 403
2023
Q4 		– Sell
-176
Closed -$19.8K – 449
2023
Q3 		$19.8K Hold
176
– – 0.02% 382
2023
Q2 		$16.6K Hold
176
– – 0.02% 446
2023
Q1 		$17.8K Hold
176
– – 0.02% 389
2022
Q4 		$21K Hold
176
– – 0.02% 329
2022
Q3 		$19K Hold
176
– – 0.02% 373
2022
Q2 		$17K Hold
176
– – 0.01% 441
2022
Q1 		$17K Buy
+176
New +$14.9K 0.01% 563

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Riverview Trust Company's NBIX Position: Q2 2025 in Review

Riverview Trust Company sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 176 shares — an estimated $19.5K sold.

Riverview Trust Company first reported a position in NBIX in Q1 2022 and held it in 12 quarters. The position peaked at $24.7K in Q4 2024. 585 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • Riverview Trust Company reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • Riverview Trust Company sold 176 Neurocrine Biosciences shares in Q2 2025, an estimated $19.5K.
  • Riverview Trust Company first reported a position in Neurocrine Biosciences in Q1 2022 and held it in 12 quarters.
  • Riverview Trust Company's Neurocrine Biosciences position peaked at $24.7K in Q4 2024.
  • 585 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Riverview Trust Company's 13F filing for Q2 2025, filed 21 Jul 2025.